Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) introduced the development of its aggressive “Go to Market” technique for enlargement of SofPulse® medical gadget distribution by the U.S. Division of Protection (DoD), Veterans Administration (VA) and different federal healthcare services (FHS) contracts.
President and Chief Industrial Officer of Endonovo’s Medical Division, Ira Weisberg, is overseeing the “Go to Market” technique and is actively partaking in contract talks geared towards increasing gross sales and advertising efforts for licensing and distribution contracts of SofPulse® by the federal government channels.
The VA and DoD are accountable for offering healthcare and different companies to members of the army and veteran populations in the USA. Each the VA and DoD have established techniques for buying items and companies, which can embody particular necessities for contractors, corresponding to registered Small Enterprise Administration (SBA) corporations or Service-Disabled Veteran-Owned Small Enterprise (SDVOSB) corporations.
Weisberg Leads Negotiations.
In making the announcement, Weisberg commented: “We’re actively negotiating with a veteran-owned firm that may present for the introduction of SofPulse® into the Division of Protection, Veterans Administration and different federal healthcare services. Offering SofPulse®, an FDA cleared medical gadget, designed to offer a viable different to opioid ache administration for surgical sufferers to all our DoD and VA physicians, hospitals and sufferers presents a ache administration answer that has proven to offer sufferers with improved post-surgical outcomes.
Weisberg continued: “Endonovo is increasing our mission to turn out to be a first-rate provider into the federal provide system and increasing the advantages of SofPulse®. We’re presently engaged in talks with a world-class authorities and tutorial collaboration to carry wise ache administration strategies to the army.”
“NewCo” Spin–Off to Focus on SofPulse®
Endonovo is presently increasing gross sales and advertising efforts in help of its “Go to Market” technique with the assumption that new administration and gross sales efforts can take the beforehand introduced spin-off, NewCo, centered on SofPulse® medical units and IP to generate greater than $100 million in gross sales by2024. The projected timeline for the NewCo to be listed as a NASDAQ firm, shall be clarified over the primary half of 2023.
In accordance with Weisberg: “Growing gross sales with established authorities contractors is an environment friendly solution to proceed the commercialization of SofPulse®. We consider that by including giant authorities contracts to our gross sales and distribution channels by our army and authorities affected person populations we will attain the $50 million projected pre-money valuation for NewCo post-closing of the medical gadget property from Endonovo.”
VA.gov stories: “The Veterans Well being Administration (VHA) is the most important built-in well being care system in the USA, offering care at 1,298 well being care services, together with 171 VA Medical Facilities and 1,113 outpatient websites of care of various complexity (VHA outpatient clinics) to over 9 million Veterans enrolled within the VA well being care program.”
Americanaddictioncenters.org stories: “The nationwide opioid disaster have an effect on each demographic however none so closely as veterans. In accordance with Robert Wilkie, the Secretary of Veterans Affairs, veterans are twice as more likely to die from an opioid overdose than civilian People. U.S. army veteran have been closely impacted by the opioid overdose disaster, with drug overdose mortality charges growing by 53% from 2010–2019.”
PAIN MANAGEMENT PROGRAM INTRODUCED
Weisberg continued: “As an vital aspect of our ‘Go to Market’ technique, Endonovo has developed a ‘Ache Enchancment Program’ (PIP) to concentrate on army and veterans’ surgical outcomes. We consider the PIP initiative will pave the way in which to enhance the surgical outcomes and cut back opioid use for our lively army heroes, their households in addition to our veterans. Our Firm is dedicated to bettering the standard of lifetime of our little kids in lively army service in addition to those that have already served. Bringing SofPulse® non- opioid ache discount advantages to our army, retired army veterans and different federal staff is an obligation we don’t take flippantly.”
SofPulse® is a medical gadget that’s designed to offer a viable different to opioid ache administration for surgical sufferers. The gadget makes use of Pulsed Electro-Magnetic Area (PEMF) remedy to cut back ache and edema (swelling) following surgical procedure. PEMF remedy is a non-invasive therapy that makes use of low-frequency electromagnetic fields to stimulate the physique’s pure therapeutic processes and has proven to be a protected and efficient different to opioids for managing ache and lowering edema following surgical procedure.
Weisberg concluded: “I’m extraordinarily pleased with our Firm in its fast completion of the PIP initiative to carry a confirmed drug-free ache administration gadget to our army, authorities and veterans affected person populations. Extending the advantages of SofPulse® into affected person populations which can be severely impacted by the opioid disaster was considered by our Firm as a mission crucial requirement for the re-launch of SofPulse® as a holistic drug-free different to opioids for surgical ache administration.”
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is at present structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals® therapeutic units for ache aid, normal wellness and wound curatives with a lot of its merchandise marketed beneath the SofPulse® model identify; and its Construct Up Technique – buying complementary specialty service suppliers within the building business.
Safe Harbor Statement
This press launch incorporates data that constitutes forward-looking statements made pursuant to the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. All statements, traits, evaluation, and different data contained on this press launch together with phrases corresponding to “anticipate”, “consider”, “plan”, “estimate”, “count on”, “intend” and different related expressions of opinion, represent forward-looking statements. Any such forward-looking statements contain dangers and uncertainties that might trigger precise outcomes to vary materially from any future outcomes described throughout the forward-looking statements. Threat components that might contribute to such variations embody these issues extra absolutely disclosed within the Firm’s stories filed with the Securities and Trade Fee. The forward-looking data supplied herein represents the Firm’s estimates as of the date of the press launch, and subsequent occasions and developments might trigger the Firm’s estimates to vary. The Firm particularly disclaims any obligation to replace the forward-looking data sooner or later. Subsequently, this forward-looking data shouldn’t be relied upon as representing the Firm’s estimates of its future monetary efficiency as of any date subsequent to the date of this press launch.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
(800) 701-1223 Ext. 108
Gregory A. McAndrews
Greg McAndrews & Associates